Corrigendum to "Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer" [The Breast 17 (2008) 484-491] (DOI:10.1016/j.breast.2008.02.010);Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer

Breast

Volumn 17, Issue 5, 2008, Pages 484-491

  Linderholm, Barbro K ^a,c   Gruvbreger Saal, Sofia ^b   Fernö, Mårten ^b   Bendahl, Pär Ola ^b   Malmström, Per ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Early relapses; Premenopausal lymph node negative breast cancer; S phase fraction (SPF); Urokinase type plasminogen activator (uPA); Vascular endothelial growth factor (VEGF)

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; TAMOXIFEN; UROKINASE; VASCULOTROPIN;

ADJUVANT THERAPY; ADULT; AGE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CELL CYCLE S PHASE; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; TIME; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 53149153529     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2009.02.007     Document Type: Erratum

References (25)

1. Jänicke F., Prechtl A., Thomssen C., Harbeck N., Meisner C., Untch M., et al. German N0 Study Group. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator inhibitor type-1. J Natl Cancer Inst 93 (2001) 913-920
2. Look M.P., van Putten W.L.J., Duffy M.J., Harbeck N., Christensen I.J., Thomssen C., et al. Pooled analysis of prognostic impact of uPA and PAI-1 in 8,377 breast cancer patients. J Natl Cancer Inst 94 (2002) 116-128
3. Hildenbrand R., Dilger I., Horlin A., and Stutte H.J. Urokinase and macrophages in tumor angiogenesis. Br J Cancer 72 (1995) 812-823
4. Scott P.A.E., Smith K., Poulsom R., De Benedetti A., Bicknell R., and Harris A.L. Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relation to eIF-4E. Br J Cancer 77 (1998) 2120-2128
5. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306-1309
6. Pepper M.S., Ferrara N., Orci L., and Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 181 (1991) 902-906
7. Gasparini G., Toi M., Gion M., Verderio P., Dittadi R., Hanatani M., et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89 (1997) 139-147
8. 165) is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16 (1998) 3121-3128
9. Eppenberg U., Kueng W., Schlaeppi J.M., Roesel J.L., Benz C., Mueller H., et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 16 (1998) 3129-3136
10. Gasparini G., Toi M., Miceli R., Vermeulen P.B., Dittadi R., Biganzoli E., et al. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am 5 (1999) 101-111
11. Linderholm B., Grankvist K., Wilking N., Johansson M., Tavelin B., and Henriksson R. Correlation of vascular endothelial growth factor (VEGF) and survival, metastasis sites and responsiveness to adjuvant systemic treatment in primary node-positive breast carcinoma. J Clin Oncol 18 (2000) 1423-1431
12. De Paola F., Granato A.M., Scarpi E., Monti F., Medri L., Bianchi S., et al. Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer. Int J Cancer 98 (2002) 228-233
13. Ludovini V., Sidoni A., Pistola L., Bellezza G., De Angelis V., Gori S., et al. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients. Breast Cancer Res Treat 81 (2003) 159-168
14. Hyder S.M., Nawas Z., Chiappetta C., and Stancel G.M. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60 (2000) 3183-3190
15. Hilsenbeck S.G., Ravdin P.M., de Moor C.A., Chamness G.C., Osborne K., and Clark G.M. Time-dependence of hazard ratios for prognostic factors in breast primary cancer. Breast Cancer Res Treat 52 (1995) 227-237
16. Malmström P., Bendahl P.-O., Boiesen P., Bru{combining double acute accent}nner N., Idvall I., and Fernö M. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham prognostic index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 19 (2001) 2010-2019
17. Baldetorp B., Dalberg M., Holst U., and Lindgren G. Statistical evaluation of cell kinetic data from DNA flow cytometry (FCM) by the em algorithm. Cytometry 10 (1989) 695-705
18. Sigurdsson H., Baldetorp B., Borg A., Dalberg M., Ferno M., Killander D., et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 322 (1990) 1045-1053
19. Hiddemann W., Schumann J., Andreeff M., Barlogie B., Herman C.J., Leif R.C., et al. Conventional nomenclature for DNA cytometry. Cytometry 5 (1984) 445-446
20. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 69 (1982) 239-241
21. Gray R.J. Flexible methods for analyzing survival data using splines, with application to breast cancer prognosis. J Am Statist Assoc 87 (1992) 942-951
22. Ulm K., Jänicke F., Pache L., and Dannegger F. Change in prognostic impact of uPA and PAI-1 in node-negative breast cancer patients during follow-up. Breast Cancer Res Treat 37 S (1996) 59
23. Colleoni M., Rocca A., Sandri M.T., et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13 (2002) 73-82
24. Linderholm B., Lindh B., Beckman L., et al. The prognostic value of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in 1307 patients with primary breast cancer. Clin Breast Cancer 4 (2003) 340-347
25. Kim L.S., Huang S., Lu W., Lev D.C., and Price J.E. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastasis in nude mice. Clin Exp Metastasis 21 (2004) 107-118